Biora Therapeutics, Inc.

NasdaqGM:BIOR Stock Report

Market Cap: US$6.1m

Biora Therapeutics Valuation

Is BIOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BIOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BIOR's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOR?

Key metric: As BIOR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIOR. This is calculated by dividing BIOR's market cap by their current revenue.
What is BIOR's PS Ratio?
PS Ratio6.9x
SalesUS$892.00k
Market CapUS$6.14m

Price to Sales Ratio vs Peers

How does BIOR's PS Ratio compare to its peers?

The above table shows the PS ratio for BIOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average24.2x
ONVO Organovo Holdings
59.7x43.8%US$6.1m
ABVC ABVC BioPharma
12.9xn/aUS$6.6m
SNGX Soligenix
22.8x44.2%US$8.3m
TTOO T2 Biosystems
1.4xn/aUS$10.5m
BIOR Biora Therapeutics
6.9x60.3%US$6.1m

Price-To-Sales vs Peers: BIOR is good value based on its Price-To-Sales Ratio (6.9x) compared to the peer average (24.2x).


Price to Sales Ratio vs Industry

How does BIOR's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
MRNA Moderna
3.1x6.8%US$15.82b
INCY Incyte
3.4x8.9%US$13.82b
BIOR 6.9xIndustry Avg. 9.6xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BIOR is good value based on its Price-To-Sales Ratio (6.9x) compared to the US Biotechs industry average (9.7x).


Price to Sales Ratio vs Fair Ratio

What is BIOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.9x
Fair PS Ratio10.6x

Price-To-Sales vs Fair Ratio: BIOR is good value based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (10.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIOR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.67
US$34.00
+1,935.9%
32.4%US$45.00US$23.00n/a2
Nov ’25US$3.35
US$97.50
+2,811.0%
53.8%US$150.00US$45.00n/a2
Oct ’25US$4.97
US$97.50
+1,863.7%
53.8%US$150.00US$45.00n/a2
Sep ’25US$6.97
US$97.50
+1,299.1%
53.8%US$150.00US$45.00n/a2
Aug ’25US$6.54
US$103.00
+1,474.2%
45.6%US$150.00US$56.00n/a2
Jul ’25US$6.30
US$103.00
+1,535.2%
45.6%US$150.00US$56.00n/a2
Jun ’25US$6.40
US$103.00
+1,509.9%
45.6%US$150.00US$56.00n/a2
May ’25US$6.42
US$103.00
+1,504.4%
45.6%US$150.00US$56.00n/a2
Apr ’25US$7.35
US$278.00
+3,680.8%
79.9%US$500.00US$56.00n/a2
Mar ’25US$11.50
US$278.00
+2,317.4%
79.9%US$500.00US$56.00n/a2
Feb ’25US$9.39
US$278.00
+2,860.0%
79.9%US$500.00US$56.00n/a2
Jan ’25US$13.50
US$278.00
+1,959.3%
79.9%US$500.00US$56.00n/a2
Dec ’24US$13.50
US$278.00
+1,959.3%
79.9%US$500.00US$56.00n/a2
Nov ’24US$19.90
US$518.67
+2,506.4%
74.3%US$1,000.00US$56.00US$3.353
Oct ’24US$21.70
US$825.00
+3,701.8%
21.2%US$1,000.00US$650.00US$4.972
Sep ’24US$29.80
US$825.00
+2,668.5%
21.2%US$1,000.00US$650.00US$6.972
Aug ’24US$39.40
US$825.00
+1,993.9%
21.2%US$1,000.00US$650.00US$6.542
Jul ’24US$38.50
US$825.00
+2,042.9%
21.2%US$1,000.00US$650.00US$6.302
Jun ’24US$44.20
US$825.00
+1,766.5%
21.2%US$1,000.00US$650.00US$6.402
May ’24US$23.30
US$825.00
+3,440.8%
21.2%US$1,000.00US$650.00US$6.422
Apr ’24US$27.70
US$825.00
+2,878.3%
21.2%US$1,000.00US$650.00US$7.352
Mar ’24US$29.50
US$825.00
+2,696.6%
21.2%US$1,000.00US$650.00US$11.502
Feb ’24US$40.50
US$825.00
+1,937.0%
21.2%US$1,000.00US$650.00US$9.392
Jan ’24US$32.93
US$1,250.00
+3,696.5%
20.0%US$1,500.00US$1,000.00US$13.502
Dec ’23US$60.53
US$1,250.00
+1,965.3%
20.0%US$1,500.00US$1,000.00US$13.502
Nov ’23US$93.00
US$1,250.00
+1,244.1%
20.0%US$1,500.00US$1,000.00US$19.902

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies